Insight

First-Line Procarbazine, CCNU, and Vincristine With Radiotherapy in IDH-Mutant Oligodendroglioma – Journal of Clinical Oncology

Salah Eddine O. Kacimi/researchgate.net

Oct 15, 2024, 16:40

First-Line Procarbazine, CCNU, and Vincristine With Radiotherapy in IDH-Mutant Oligodendroglioma – Journal of Clinical Oncology

Journal of Clinical Oncology shared a post on X:

“Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.”

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma

Authors: Salah Eddine O. Kacimi, et al.

First-Line Procarbazine, CCNU, and Vincristine With Radiotherapy in IDH-Mutant Oligodendroglioma - Journal of Clinical Oncology

cancer cancer awareness cancer care CCNU fight against cancer Global fight against cancer JCO Journal of Clinical Oncology Oligodendroglioma OncoDaily Oncology Procarbazine radiotherapy Salah Eddine O. Kacimi

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer